THE GG rs292001 GENOTYPE PREVAILS IN SERONEGATIVE FOR ANA AND ANTI-dsDNA ANTIBODIES PATIENTS WITH LUPUS NEPHRITIS

Maria Radanova1, Kamelia Bratoeva2, Neshe Nazifova-Tasinova1, Miglena Todorova1, Vasil Vasilev3, Diana Ivanova1

1Department of Biochemistry, Molecular Medicine and Nutrigenomics, Medical University of Varna
2Department of Physiology and Pathophysiology, Medical University of Varna
3Clinics of Nephrology, University Hospital - “Tzari tza Ioanna - ISUL”, Medical University - Sofia

ABSTRACT
Rs292001 is single nucleotide polymorphism in non-coding regions of the C1QA gene. C1q is a subcomponent of the C1 first component of the classical pathway of complement activation. Rs292001 was investigated for an association with some conventional immunological markers of lupus nephritis (LN) activity in systemic lupus erythematosus (SLE) patients – levels of C1q, C3, C4, anti-C1q, anti-nuclear (ANA) and anti-ds-DNA autoantibodies.

Genomic DNA was isolated from peripheral blood of 18 patients with biopsy-proven LN. SNP genotyping for the presence of rs292001 was performed by quantitative real-time PCR method. Presence of complement C1q, C3 and C4 and anti-C1q autoantibodies was screened by ELISA. ANA and anti-dsDNA antibodies were detected by double immunodiffusion assays and indirect immunofluorescence.

We found that the GG rs292001 genotype prevailed in seronegative for ANA and anti-dsDNA antibodies LN patients (p=0.008; p<0.012). The AA rs292001 genotype showed a trend towards lower serum C1q levels.

These results reaffirm a previously established probable protective role of the G allele against the clinical activity of the SLE.

Keywords: rs292001, ANA, anti-dsDNA Abs, C1q, Lupus nephritis

INTRODUCTION
Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). The complement proteins C1q, C3 and C4 are deposited at the site of inflammation in the kidney and play an important role in the pathogenesis of LN. It is well known that hereditary C1q deficiency is strongly related to SLE, but there are several and inconsistent studies exploring single nucleotide poly-
morphisms (SNPs) of the C1q gene cluster in relation to the pathogenesis of SLE (1-10).

Genes encoding C1q chains (6A-, 6B- and 6C-) are grouped in a cluster on chromosome 1. The C1QA gene includes two introns and two exons. The rs292001 is SNP in the second intron of C1QA gene. According to several studies, the AA rs292001 genotype seems to associate with adult and juvenile SLE and LN (3,6,10).

The aim of the present study was to investigate whether rs292001 SNP, previously reported with association to SLE, correlates with some conventional immunological markers of LN activity – low levels of C1q, C3 and C4, high levels of anti-C1q, anti-nuclear (ANA) and anti-dsDNA autoantibodies.

**MATERIALS AND METHODS**

**Study Subjects**

18 serum samples from patients with SLE and biopsy-proven LN (World Health Organization Class I, II, III, IV, V and VI) were collected in the Clinics of Nephrology, University Hospital “Tzaritza Ioanna – ISUL” - Sofia, Bulgaria. The LN group included 16 (89%) women and 2 (11%) men, at an average age of 36.7±10.8 years (ranging from 23 to 58). The duration of LN lasted from 0.5 to 28 years, with an average of 9.64±7.62 years. The diagnosis of LN was based on clinical and laboratory parameters including proteinuria, urinary sediment, creatinine level, and erythrocyte sedimentation rate. The inclusion criteria were defined as proteinuria 500 mg/24 hr or higher in the last 10 days, erythrocyturia as 8 RBC per microliter or higher, renal dysfunction as any increase in creatinine value at any time of the history of the disease, and renal involvement as any of the two of the above-mentioned variables. Each patient signed a consent form at enrolment.

**Genotyping for rs292001**

Genomic DNA was isolated from whole blood using QIAamp DNA Blood MiniKit (QIAGEN GmbH, Hilden, Germany) and was stored at –20°C. Detection of the SNPs rs292001 was carried out using a validated TaqMan genotyping assay (Applied Biosystems, Foster City, CA). SNP genotyping was performed using an allelic discrimination assay (TaqMan® SNP Genotyping Assays, Applied Biosystems, Foster City, CA) using the 7500 Real-Time PCR System and genotypes were read using automated software (Applied Biosystems, Foster City, CA). Reactions were run in 10μl volumes using an amplification protocol of 50°C for 2min, 95°C for 10min, followed by 40 cycles of 95°C for 15s, then 60°C for 1min.

**Measurement of Anti-C1q Antibodies and Complement Protein**

Anti-C1q autoantibody levels were measured in human serum samples by ELISA under 0.75 M NaCl conditions as described previously (11,12). The concentrations of C1q, C4 and C3 antigens in serum were measured by means of a double-ligand ELISA (9).

**Measurement of ANA and Anti-dsDNA Antibodies**

The presence of ANA and anti-dsDNA antibodies were detected by double immunodiffusion assays and indirect immunofluorescence.

**Statistical Analysis**

Statistical analysis was carried out using software GraphPad Prism 5.01. Quantitative data were expressed as mean ±SD. The unpaired t test with Welch’s corrections for 2-group comparisons was used. Statistical significance was considered as p<0.05.

**RESULTS**

**Characterization of Investigated Subjects**

Eight of all 18 patients were with clinically active LN and the remaining 9 patients were in complete remission. The complete remission was defined as urinary protein excretion <0.5 g/day, normal urinary sediment (<8 RBC/µl, <8 WBC/µl, absence of casts other than hyaline), serum creatinine and albumin concentrations in reference ranges. One patient had class I, 3 – had class II, 12 – had class IV and 2 – had class V glomerulonephritis. There were no patients with LN classes III and VI. The characteristics and main pathological data of 18 LN patients at the time of renal biopsy are listed in Table 1.

**Investigation for an Association Between rs292001 and the Levels of C1q, C3, C4 and Anti-C1q Autoantibodies in LN Patients**

We analyzed the possible association of rs292001 with the immunological features of lupus nephritis activity – low levels of C1q, C4 and C3 and high levels of anti-C1q autoantibodies. We observed
no significant associations between the markers of disease activity and rs292001 genotypes in the dominant model in the patient group (p>0.05 for all investigated immunological parameters, specifically GG vs. GA/AA for Clq levels – p=0.075; GG vs. GA/AA for C3 levels – p=0.132; GG vs. GA/AA for C4 levels – p=0.343 and GG vs. GA/AA for anti-C1q Abs levels – p=0.495). Only the carriers of A rs292001 allele showed a trend towards lower serum Clq levels.

**DISCUSSION**

Genetic predisposition to SLE and LN is dependent on complex interactions of many genes and environmental and hormonal factors (13). Significant associations with the development of SLE, including LN, were established for rs292001 in studies by Martens et al. (2009), Zervou et al. (2011) and Mosaad et al. (2015). They found that patients with A allele and AA genotype of rs292001 could be considered a susceptibility risk factor for SLE, juvenile SLE (jSLE) and LN in Dutch, Turkish and Egyptian cohorts (3,6,10). In these studies, the rs292001 was not associated with the disease severity or with a serum concentration of C1q or/and anti-C1q antibodies. In contrast, the C1q rs292001 SNP was not associated with the risk of SLE and LN in two Caucasian cohorts – Polish (14) and Bulgarian ones (9).

**Table 1. Patient’s characteristics**

| Patient’s characteristics                                      | Value       |
|----------------------------------------------------------------|-------------|
| Number                                                          | 18          |
| Sex – female, n (%)                                            | 16 (89%)    |
| Median age (years, range)                                       | 37 (23 – 58)|
| Median duration of disease (years, range)                      | 10 (0.5 – 28)|
| Complement Clq (mean, normal range) g/l                        | 69 (59 – 178)|
| Complement C4 (mean, normal range) g/l                         | 130 (84 – 396)|
| Complement C3 (mean, normal range) g/l                         | 910 (612 – 1444)|
| Anti-C1q antibodies (mean, cut off)                            | 2.029 (2.139)|
| Anti-nuclear antibodies (ANA) (+) № (%)                         | 11 (61)     |
| Anti-double stranded DNA antibodies (anti-dsDNA) (+) № (%)      | 8 (44)      |
| Serum creatinine (mean, range) µmol/l                          | 99 (56 – 519)|
| eGFR (mean) mL/min/1.73sqm                                     | 72          |
| Serum total protein (mean, range) g/L                           | 63 (64 – 83)|
| Serum albumin (mean, range) g/L                                 | 37 (35 – 50)|
| Proteinuria (mean, range) g/24h                                | 1.887 (0.069 – 6.970)|
| Urinary sediment (+) № (%)                                      | 5/18 (28)   |

61% and 44% of LN patients were seropositive for ANA and anti-dsDNA Abs, respectively. Eight patients from the group of LN patients over 40 years of age were seropositive for ANA (8/11, 73%) and 6 – for anti-dsDNA Abs (6/11, 55%). In the group of younger patients – below 40 years of age – the rates were 57% seropositive for ANA (4/7) and 43% - sero-positive for anti-dsDNA Abs patients (3/7). We examined the possible association of the rs292001 with ANA and anti-dsDNA antibodies. Genotype distribution between positive and negative for ANA and anti-dsDNA antibodies LN patients in the dominant model was compared. It was established that the GG rs292001 genotype prevailed in seronegative for ANA and anti-dsDNA antibodies LN patients (p=0.008; p<0.012) (Fig. 1A and 1B).
In the present study, we found that the GG rs292001 genotype prevailed in LN patients seronegative for ANA and for anti-dsDNA antibodies. It is known that ANA and anti-dsDNA antibodies are considered a reliable marker for SLE activity and are implicated in the pathogenesis of LN (15). Therefore, our results are in accordance with several studies, which speculate that the GG rs292001 genotype probably provides a protective effect for juvenile systemic lupus erythematosus (jSLE) and LN (10) via an unexplained mechanism. Certainly, a limitation of our study is the relatively small sample size (only 18 LN patients). Nevertheless, the established associations add new information about the possible key role of this non-coding SNP in the pathogenesis of SLE.

The rs292001 SNP is a subject of several new studies and its role in other autoimmune and immune-mediated diseases is actively investigated. For example, the rs292001 A allele has been associated with an increased risk for type 2 diabetes (T2D) (17), for rheumatoid arthritis (16), for Behçet’s disease (18) and for schizophrenia (19).

CONCLUSIONS

Our results reaffirm a previously established probable protective role of the G allele against the clinical activity of the SLE.

REFERENCES

1. Racila DM, Sontheimer C, Sheffield A, Wisnieski JJ, Racila E, Sontheimer RD. Homozygous single nucleotide polymorphism of the complement C1QA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus. Lupus 2003;12(2):124-32.
2. Chew CH, Chua KH, Lian LH, Puah SM, Tan SY. PCR–RFLP genotyping of C1q mutations and single nucleotide polymorphisms in Malaysian patients with systemic lupus erythematosus. Hum Biol. 2008;80(1):83-93.
3. Martens HA, Zuurman MW, de Lange AH, Nolte IM, van der Steege G, Navis GJ, et al. Analysis of C1q polymorphisms suggests association with systemic lupus erythematosus, serum C1q and CH50 levels and disease severity. Ann Rheum Dis. 2009;68(5):715-20.
4. Namjou B, Gray-McGuire C, Sestak AL, Gilkeson GS, Jacob CO, Merrill JT, et al. Evaluation of C1q genomic region in minority racial groups of lupus. Genes Immun. 2009;10(5):517-24.
5. Rafiq S, Frayling TM, Vyse TJ, Cunninghame Graham DS, Eggleton P. Assessing association of common variation in the C1Q gene cluster with systemic lupus erythematosus. Clin Exp Immunol. 2010;161(2):284-9.
6. Zervou MI, Vazgiourakis VM, Yilmaz N, Kontaki E, Trouw LA, Toes RE, et al. TRAF1/C5, eNOS, C1q, but not STAT4 and PTPN22 gene polymorphisms are associated with genetic susceptibility to
The GG rs292001 Genotype Prevails in Seronegative for ANA and Anti-dsDNA Antibodies Patients with Lupus Nephritis

systemic lupus erythematosus in Turkey. Hum Immunol. 2011;72(12):1210-3.

7. Cao CW, Li P, LuanHX, Chen W, Li CH, Hu CJ, et al. Association study of C1qA polymorphisms with systemic lupus erythematosus in a Han population. Lupus 2012;21(5):502-7.

8. Devaraju P, Reni BN, Gulati R, Mehra S, Negi VS. Complement C1q and C2 polymorphisms are not risk factors for SLE in Indian Tamils. Immunobiology 2014;219(6):465-8.

9. Radanova M, Vasilev V, Dimitrov T, Deliyska B, Ilkonov V, Ivanova D. Association of rs172378 C1q gene cluster polymorphism with lupus nephritis in Bulgarian patients. Lupus, 2015;24(3):280-9.

10. Mosaad YM, Hammad A, Fawzy Z, El-Refaaey A, Tawhid Z, Hammad EM, et al. C1q rs292001 polymorphism and C1q antibodies in juvenile lupus and their relation to lupus nephritis. Clin Exp Immunol. 2015;182(1):23-34.

11. Radanova M, Tsacheva I, Argirova T, Kojuharova M. Interaction of recombinant globular head regions of C1q with normal and autoimmune sera. Annulare de l’Universite de Sofia “St. Kliment Ohridski”, Faculte de biologie, 2005;96(4):17-24.

12. Tsacheva I, Radanova M, Todorova N, Argirova T, Kishore U. Detection of autoantibodies against the globular domain of human C1q in the sera of systemic lupus erythematosus patients. Mol Immunol. 2007;44(8):2147-51.

13. Tsao BP. The genetics of human systemic lupus erythematosus. Trends Immunol. 2003;24(11):595-602.

14. Korczowska I, Trzybulska D, Ostanki L, Brzosko M, Rosińska M, Niemir Z, et al. Polymorphism of C1q complement (rs292001) occurrence in systemic lupus erythematosus patients. Borgis Prog Med Sci. 2012;12:981-5.

15. Meroni PL, Shoenfeld Y. Systemic lupus erythematosus and the SLE galaxy. Autoimmun Rev 2010;10(1):1-2.

16. Trouw LA, Daha N, Kurreeman FA, Böhringer S, Goulielmos GN, Westra HJ, et al. Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis. Clin Exp Immunol. 2013;173(1):76-83.

17. Goulielmos GN, Samonis G, Apergi M, Christofaki M, Valachis A, Zervou MI, et al. C1q but not mannos-binding lectin (Mbl-2) gene polymorphisms are associated with type 2 diabetes in the genetical-